Precision Imaging to Evaluate Kaposi Sarcoma (PRIME-KS): A Device Feasibility Trial

Launched by WASHINGTON UNIVERSITY SCHOOL OF MEDICINE · Dec 20, 2024

Keywords

ClinConnect Summary

The PRIME-KS trial is studying a new way to take detailed 3D images of Kaposi sarcoma (KS), a type of cancer that can occur in people with HIV/AIDS. This trial aims to improve how doctors assess the size and shape of KS lesions, which are the growths caused by this cancer. The new imaging system, called SkinScan3D, uses advanced technology to capture more accurate information than traditional 2D images, helping to better monitor how well treatments are working over time.

To participate in this trial, you need to be at least 18 years old and have been diagnosed with Kaposi sarcoma, with at least three visible lesions on your skin. If you join, you can expect to have your KS lesions photographed using this innovative imaging technology. This could help researchers understand how KS responds to different treatments and may lead to better care for patients in the future. The trial is currently recruiting participants, so if you meet the criteria and are interested, you may want to learn more about it.

Gender

ALL

Eligibility criteria

• Eligibility Criteria:
• • Have been diagnosed with histologically or cytologically proven Kaposi sarcoma (KS).
• • Has at least 3 cutaneous Kaposi sarcoma lesions.
• • At least 18 years of age.
• • Ability to understand and willingness to sign an IRB approved written informed consent document.